Preclinical PET Imaging and Toxicity Study of a 68 Ga-Functionalized Polymeric Cardiac Blood Pool Agent.
Katayoun SaatchiFrançois BénardNavjit HundalJoshua GrimesSergey ShcherbininMaral PourghiasianDonald E BrooksAnna CellerUrs O HäfeliPublished in: Pharmaceutics (2023)
Cardiac blood pool imaging is currently performed almost exclusively with 99m Tc-based compounds and SPECT/CT imaging. Using a generator-based PET radioisotope has a few advantages, including not needing nuclear reactors to produce it, obtaining better resolution in humans, and potentially reducing the radiation dose to the patient. When the shortlived radioisotope 68 Ga is used, it can be applied repeatedly on the same day-for example, for the detection of bleeding. Our objective was to prepare and evaluate a long-circulating polymer functionalized with gallium for its biodistribution, toxicity, and dosimetric properties. A 500 kDa hyperbranched polyglycerol was conjugated to the chelator NOTA and radiolabeled rapidly at room temperature with 68 Ga. It was then injected intravenously into a rat, and gated imaging allowed us to easily observe wall motion and cardiac contractility, confirming the suitability of this radiopharmaceutical for cardiac blood pool imaging. Internal radiation dose calculations showed that the radiation doses that patients would receive from the PET agent would be 2.5× lower than those from the 99m Tc agent. A complete 14-day toxicology study in rats concluded that there were no gross pathology findings, changes in body or organ weights, or histopathological events. This radioactive-metal-functionalized polymer might be a suitable non-toxic agent to advance for clinical application.
Keyphrases
- pet ct
- pet imaging
- high resolution
- room temperature
- left ventricular
- positron emission tomography
- computed tomography
- end stage renal disease
- quantum dots
- oxidative stress
- chronic kidney disease
- heart failure
- radiation therapy
- drug delivery
- newly diagnosed
- prognostic factors
- mass spectrometry
- molecularly imprinted
- stem cells
- patient reported outcomes
- cancer therapy